Search results for: Determining Value
Filter search results
NICE Decisions: Cost-effectiveness is the Most Significant Predictor
21 November 2013
…(NICE) undertakes appraisals of selected technologies and issues guidance intended to ensure quality and value for money. Its decisions are binding within the NHS and also affect decisions by health…
Patricia Cubi-Molla
4 September 2015
Dr Patricia Cubi-Molla, PhD, Senior Principal Economist at the Office of Health Economics (OHE), specialising in value assessment and healthcare decision-making. She leads OHE’s research theme on Value, Affordability, and Decision-Making and…
Pricing Variations Within and Across Countries: Gauging Efficiency
25 February 2014
…Danzon of the Wharton School at the University of Pennsylvania to examine value-based pricing for pharmaceuticals. The research explores which approaches to pricing can produce the greatest efficiency within and…
Use of Cost-effectiveness Evidence in US Health Care: Seminar Briefing
1 April 2014
Just published by OHE, this Seminar Briefing summarises remarks at an OHE Lunchtime Seminar by Dr James Chambers of the Center for the Evaluation of Value and Risk in Health…
OHE at the 2019 International Health Economics Association (iHEA) World Congress
5 July 2019
…issues concerning the quality of care, variation of hospital readmission, waiting time for hospital admission etc. Quantifying the Life-Cycle Value of Innovative Medicines: The Case of Risperidone and Second-Generation Antipsychotics…
Spotlight on OHE: NICE, Biosimilars, HTA
17 June 2014
…NICE assesses the value of a health technology is scheduled to be completed in June 2014. In a presentation at the PharmaAccess Leader’s Forum, Martin Garau summarised the proposed changes…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
…policy hurdles related to evidence development and acceptance, value assessment and reimbursement pathways,… Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular…
OHE at ISPOR Europe: Posters
13 November 2014
…Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014 from Office of Health Economics Koonal Shah and Brendan Mulhern (University of Sheffield) The Expanding Value Footprint of Oncology Treatments. Ispor poster expanding_value_footprint_oncology_treatment_jmf_oct2014 from Office of…
Adult Versus Adolescent Preferences for EQ-5D-Y Health States
15 April 2019
…launched a Health Preference Research Special Interest Group, dedicated to understanding the value of health and health-related goods and services. OHE’s Koonal Shah was invited to give the Group’s inaugural…